RELAPSED/REFRACTORY AML
Clinical trials for RELAPSED/REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY AML trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes on Hard-to-Treat blood cancers in early trial
Disease control OngoingThis early-phase study tests an experimental oral drug, AUTX-703, in adults whose acute myeloid leukemia or myelodysplastic syndromes have returned or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:48 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat leukemia
Disease control OngoingThis early-stage trial tests a new drug called BYON4413 in 16 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have returned or not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated May 26, 2026 10:47 UTC
-
New drug combo shows promise for tough blood cancers
Disease control OngoingThis study tests a new drug called bexmarilimab combined with standard treatments for people with certain blood cancers (MDS, CMML, or AML). The goal is to find a safe dose and see if the combination helps control the disease. About 181 adults will take part, and the study is cur…
Matched conditions: RELAPSED/REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated May 22, 2026 14:04 UTC